Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Mexico says a third of 130,000 missing people might be alive, fueling criticisms by families- Haunting Giant Squid Surfaces in Japan and Devours Its Prey (Video)
- Brilliant and Gleaming: Excellence and Skincare Practices
- Thousands of New York City nurses set to strike Monday if deal isn't reached with hospitals
- This Week In Space podcast: Episode 188 — A New NASA Leader Rises?
- Sound Propensities: 20 Methods for helping Your Insusceptible Framework
- The most effective method to Remain Ahead in the Most recent Advanced Patterns with a Web based Advertising Degree
- Step by step instructions to Look at Compact disc Rates: A Thorough Aide
- Figure out How to Augment Eco-friendliness in Your Volvo XC40
